In-vivo assessment of retinal vessel diameters and observer variability in mice: A methodological approach.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
02
2022
accepted:
08
07
2022
entrez:
21
7
2022
pubmed:
22
7
2022
medline:
26
7
2022
Statut:
epublish
Résumé
Central retinal arteriolar (CRAE) and venular (CRVE) diameter equivalents are predictive for cardiovascular and all-cause mortality in humans. The aim of this study was to investigate the inter- and intraobserver variability for the assessment of CRAE and CRVE in mice using fluorescein contrast enhancement as compared to crude analysis. Three high quality images with (F) and without fluorescein (NF) of eight mice (type C57BL) were recorded and analysed by two independent experienced investigators to investigate interobserver variability. In addition, one investigator analysed 20 F and 20 NF images twice to investigate intraobserver variability. The time course of CRAE and CRVE vessel responses after fluorescein injection were recorded in one mouse every 30 seconds for 15 minutes. The interobserver variability was lower in F images compared to NF images for CRAE (r = 0.99, p < 0.001 vs. r = 0.65, p = 0.083) and CRVE (r = 0.99, p < 0.001 vs. r = 0.79, p = 0.019). Intraobserver variability for CRAE (r = 0.99, p < 0.001 vs. r = 0.48, p = 0.032) and CRVE (r = 0.98, p < 0.001 vs. r = 0.86, p < 0.001) were lower in F compared to NF images. Fluorescein injection induced vascular staining mimicking vessel dilation (+14%) followed by a long-lasting stable staining phase well suited for precise measurements. Measurement variability can be optimized by use of fluorescein as contrast enhancement in mice. Standardization for time of image acquisition after fluorescein injection is advisable. Translation of static retinal vessel analysis into a rodent model has the potential to bridge the research gap between proof of concept studies in animals and clinical studies in humans.
Sections du résumé
BACKGROUND
Central retinal arteriolar (CRAE) and venular (CRVE) diameter equivalents are predictive for cardiovascular and all-cause mortality in humans. The aim of this study was to investigate the inter- and intraobserver variability for the assessment of CRAE and CRVE in mice using fluorescein contrast enhancement as compared to crude analysis.
METHODS
Three high quality images with (F) and without fluorescein (NF) of eight mice (type C57BL) were recorded and analysed by two independent experienced investigators to investigate interobserver variability. In addition, one investigator analysed 20 F and 20 NF images twice to investigate intraobserver variability. The time course of CRAE and CRVE vessel responses after fluorescein injection were recorded in one mouse every 30 seconds for 15 minutes.
RESULTS
The interobserver variability was lower in F images compared to NF images for CRAE (r = 0.99, p < 0.001 vs. r = 0.65, p = 0.083) and CRVE (r = 0.99, p < 0.001 vs. r = 0.79, p = 0.019). Intraobserver variability for CRAE (r = 0.99, p < 0.001 vs. r = 0.48, p = 0.032) and CRVE (r = 0.98, p < 0.001 vs. r = 0.86, p < 0.001) were lower in F compared to NF images. Fluorescein injection induced vascular staining mimicking vessel dilation (+14%) followed by a long-lasting stable staining phase well suited for precise measurements.
CONCLUSIONS
Measurement variability can be optimized by use of fluorescein as contrast enhancement in mice. Standardization for time of image acquisition after fluorescein injection is advisable. Translation of static retinal vessel analysis into a rodent model has the potential to bridge the research gap between proof of concept studies in animals and clinical studies in humans.
Identifiants
pubmed: 35862469
doi: 10.1371/journal.pone.0271815
pii: PONE-D-22-05620
pmc: PMC9302806
doi:
Substances chimiques
Fluoresceins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0271815Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Biomed Opt. 2017 Jan 1;22(1):16005
pubmed: 28056146
Atherosclerosis. 2020 Dec;315:33-42
pubmed: 33212315
Eur J Prev Cardiol. 2020 Jan;27(2):168-176
pubmed: 31610708
Circulation. 2016 Nov 1;134(18):1328-1338
pubmed: 27682886
Obes Surg. 2019 Apr;29(4):1301-1308
pubmed: 30617916
Atherosclerosis. 2021 Aug;331:45-53
pubmed: 34344526
Sci Rep. 2021 Jul 8;11(1):14136
pubmed: 34238996
Invest Ophthalmol Vis Sci. 2012 Feb 13;53(2):650-8
pubmed: 22205599
Eur Heart J. 2007 Aug;28(16):1984-92
pubmed: 17626032
Am J Epidemiol. 2009 Dec 1;170(11):1323-32
pubmed: 19884126
JAMA. 2002 Mar 6;287(9):1153-9
pubmed: 11879113
Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2341-50
pubmed: 16723443
Hypertension. 2019 Dec;74(6):1383-1390
pubmed: 31661987
Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):1-8
pubmed: 28055098
Ophthalmology. 1999 Dec;106(12):2269-80
pubmed: 10599656
Invest Ophthalmol Vis Sci. 2017 Aug 1;58(10):4193-4200
pubmed: 28837731
Curr Protoc Mouse Biol. 2016 Mar 01;6(1):15-38
pubmed: 26928662
ILAR J. 2011;52(3):e21-31
pubmed: 21677360
Neurology. 2006 May 9;66(9):1339-43
pubmed: 16682664
Eur Heart J. 2020 Apr 14;41(15):1514-1519
pubmed: 31323685
Ann Intern Med. 2004 Feb 17;140(4):248-55
pubmed: 14970147